Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Hubert H. Humphrey Cancer Center, North Memorial Medical Center, Robbinsdale, MN 55422, USA.
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 01/2006; 97(24):1832-9. DOI: 10.1093/jnci/dji430
Source: PubMed

ABSTRACT The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was initiated in 1992 to examine cause-specific mortality reduction from screening for these four cancers in men and women. We report lung cancer detection results of the baseline screening round.
Of the 154,942 participants enrolled, who were aged 55-74 years with no history of PLCO cancers, 77,465 were randomly assigned to the intervention arm. Current or former smokers and never smokers in this arm received an initial single-view posterior-anterior chest radiograph.
In the initial screen, 5991 (8.9%, 95% confidence interval [CI] = 8.7% to 9.2%) of radiographs were suspicious for lung cancer: 8.2% (95% CI = 7.9% to 8.5%) for women and 9.6% (95% CI = 9.3% to 10.0%) for men. Rates were highest for older age groups and for smokers. Among those 5991 participants with a positive screen, 206 (3.4%, 95% CI = 3.0% to 3.9%) underwent biopsy examination, 126 (61.2%, 95% CI = 54.5% to 67.8%) of whom were diagnosed with lung cancer within 12 months of the screen (59 in women and 67 in men). The positive predictive value was 2.1% (95% CI = 1.7% to 2.5%), and 1.9 lung cancers were detected per 1000 screens. Among these cancers, 44% (95% CI = 35% to 52%) were stage I non-small-cell lung cancer. High rates of lung cancer were found in current smokers (6.3 per 1000 screens) and in former smokers who had smoked within the past 15 years (4.9 per 1000 screens). The lung cancer detection rate among never smokers was 0.4 per 1000 screens; this group accounted for 11% (95% CI = 5.6% to 16.6%) of the cancers identified.
In the baseline screen, nearly half the cancers were stage I. Whether this experience results in a reduction in lung cancer mortality is yet to be seen.

Download full-text


Available from: John K Gohagan, Jan 24, 2014
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: The detection of human cancer at an early stage presents a daunting challenge due to the lack of a specific non-invasive marker. The discovery of microRNAs (miRNAs), a class of non-coding RNAs that regulate target gene expression at the post-transcriptional level, has opened a new avenue for tumor diagnosis. Once thought to be unstable RNA molecules, miRNAs are now shown to be stably expressed in serum, plasma, urine, saliva, milk, and other body fluids. Results of the last 2 years establish the quantification of circulating miRNAs in serum/plasma as an extremely promising approach for cancer diagnosis, especially at an early stage. The aim of this chapter is to review the recently reported studies on the circulating miRNAs in cancer patients and to estimate their great potential as a class of highly specific and sensitive blood-based biomarkers for tumor classification and prognostication. Meanwhile, this chapter also addresses certain critical issues that hinder the wide application of the new approach. Some potential challenges for the transition of circulating miRNAs from a research setting to a clinical application are also highlighted. As a blood-based biomarker of cancer, circulating miRNAs have the potential to uncover cancer at an early stage and greatly reduce the worldwide health burden of cancer.
    01/1970: pages 499-532;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently available results on CT screening for lung cancer show that (1) the work-up on baseline screening can be confined to less than 15% of the individuals and to less than 6% on annual repeat screening, (2) almost all cases are detected by screening with very few diagnoses made between screening on the prompting of symptoms, and (3) over 80% of all the diagnoses are of stage I. This diagnostic performance results from following the I-ELCAP regimen of screening which defines a positive result of the initial CT in the regimen as well as the work-up leading to a diagnosis of lung cancer. The diagnostic performance raises prognostic questions as to the genuineness and curability of these screen-diagnosed lung cancers. All diagnoses of malignancy were confirmed by an expert pathology review and found to represent genuine lung cancer as defined by the 2004 World Health Organization pathologic criteria. Estimates based on growth rates suggest that about 90% of the baseline-diagnosed stage I cancers are genuine cancers, as are essentially all of those diagnosed on annual repeat screening. Preliminary results of the curability of genuine screen-diagnosed stage I lung cancers indicate a high curability rate of more than 90%. This suggests that more than a high proportion of deaths from lung cancer can be prevented by CT screening followed by early resection. Using these results, the benefit of a single round of CT screening can be determined for an individual based on the age and smoking history.
    Surgical Oncology Clinics of North America 11/2005; 14(4):761-76. DOI:10.1016/j.soc.2005.07.002 · 1.67 Impact Factor
Show more